journal article·2022-08-24Open access

Poly(trehalose methacrylate) as an Excipient for Insulin Stabilization: Mechanism and Safety

Madeline B. Gelb, Kathryn M. M. Messina, Daniele Vinciguerra, Jeong Hoon Ko, Jeffrey Collins, Mikayla Tamboline, Shili Xu, F. Javier Ibarrondo, Heather D. Maynard

ACS Applied Materials & Interfaces· Volume 14· Issue 33

Abstract

Cu-labeled pTrMA showed excretion of 78-79% ID/cc within 24 h and minimal liver accumulation at 6-8% ID/cc when studied out to 120 h. Further, the plasma lifetime of insulin in mice was not altered by added pTrMA. Formulating insulin with 2 mol equiv of pTrMA improved the stability of insulin to standard storage conditions: 46 weeks at 4 °C yielded 87.0% intact insulin with pTrMA present as compared to 7.8% intact insulin without the polymer. The mechanism by which pTrMA-stabilized insulin was revealed to be a combination of inhibiting deamidation of amino acid residues and preventing fibrillation, followed by aggregation of inactive and immunogenic amyloids all without complexing insulin into its hexameric state, which could delay the onset of insulin activity. Based on the data reported here, we suggest that pTrMA stabilizes insulin as an excipient without adverse effects in vivo and is promising to investigate further for the safe formulation of insulin.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Protein purification and stability · Pancreatic function and diabetes · Diabetes Management and Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry and Biochemistry and California NanoSystems Institute, University of California, Los Angeles, 607 Charles E. Young Drive East, Los Angeles, California 90095-1569, United States

Department of Molecular and Medical Pharmacology and Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, California 90095-1735, United States

Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1569, United States

Funding

U.S. Department of Health and Human Services · National Science Foundation

References (51)

Show source-provided references
1. World Health Organization Ten Threats to Global Health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019 (accessed 6/01/2020).
2. Kochanek, K. D.; Xu, J.; Arias, E. Mortality in the United States, 2019; U.S. Department of Health and Human Services Centers for Disease Control and Prevention, 2020.
3. World Health Organization Model List of Essential Medicines, 21st List; World Health Organization: Geneva, 2019.
4. Lendner, P. Economic Benefits of Improved Insulin Stability In Insulin Pumps. https://www.managedcaremag.com/archives/1105/1105-peer_insulinpump/ (accessed 4/26/2021).
5. 10.1023/a:101583501791610.1023/a:1015835017916 ↗
6. 10.1021/acsbiomedchemau.1c0005410.1021/acsbiomedchemau.1c00054 ↗
7. 10.1002/bit.26040080510.1002/bit.260400805 ↗
8. 10.3390/ijms1812255110.3390/ijms18122551 ↗
9. 10.1023/b:pham.0000029275.41323.a610.1023/b:pham.0000029275.41323.a6 ↗
10. 10.1111/j.1464-5491.1986.tb00809.x10.1111/j.1464-5491.1986.tb00809.x ↗
11. 10.1023/a:101587052174410.1023/a:1015870521744 ↗
12. 10.1002/anie.20140249610.1002/anie.201402496 ↗
13. 10.3109/13506129.2015.106481810.3109/13506129.2015.1064818 ↗
14. 10.1073/pnas.161663911310.1073/pnas.1616639113 ↗
15. 10.1002/adtp.20190009410.1002/adtp.201900094 ↗
16. 10.1021/acsbiomaterials.0c0130610.1021/acsbiomaterials.0c01306 ↗
17. 10.1126/scitranslmed.aba667610.1126/scitranslmed.aba6676 ↗
18. 10.1021/acs.molpharmaceut.9b0108010.1021/acs.molpharmaceut.9b01080 ↗
19. 10.1074/jbc.m116.74246010.1074/jbc.m116.742460 ↗
20. 10.1002/open.20170013110.1002/open.201700131 ↗
21. 10.1016/j.isci.2021.10257310.1016/j.isci.2021.102573 ↗
22. 10.1021/bm400304610.1021/bm4003046 ↗
23. 10.1039/c5py00121h10.1039/c5py00121h ↗
24. 10.1021/acsnano.5b0578110.1021/acsnano.5b05781 ↗
25. 10.1021/jacs.6b1077610.1021/jacs.6b10776 ↗
26. 10.1039/c7py00700k10.1039/c7py00700k ↗
27. 10.1021/acs.bioconjchem.6b0065910.1021/acs.bioconjchem.6b00659 ↗
28. 10.1021/acsmacrolett.7b0097410.1021/acsmacrolett.7b00974 ↗
29. 10.1002/mabi.20170037210.1002/mabi.201700372 ↗
30. 10.1021/acs.biomac.0c0013310.1021/acs.biomac.0c00133 ↗
31. 10.1002/mame.20210019710.1002/mame.202100197 ↗
32. 10.1208/s12249-015-0288-y10.1208/s12249-015-0288-y ↗
33. 10.1021/acs.biomac.2c0051110.1021/acs.biomac.2c00511 ↗
34. 10.3390/ijms1806124910.3390/ijms18061249 ↗
35. 10.1016/j.bpc.2010.02.00110.1016/j.bpc.2010.02.001 ↗
36. 10.1007/s11095-012-0739-z10.1007/s11095-012-0739-z ↗
37. 10.1615/jlongtermeffmedimplants.v15.i6.6010.1615/jlongtermeffmedimplants.v15.i6.60 ↗
38. Samavedi S. · 2014 · 8110.1016/B978-0-12-398523-1.00007-0 ↗
39. 10.1038/s41598-017-02691-310.1038/s41598-017-02691-3 ↗
40. 10.1002/jbm.82010061210.1002/jbm.820100612 ↗
41. 10.1021/bm050260e10.1021/bm050260e ↗
42. 10.1021/bm700541e10.1021/bm700541e ↗
43. 10.1021/bm701415210.1021/bm7014152 ↗
44. 10.2967/jnumed.109.06184610.2967/jnumed.109.061846 ↗
45. 10.1021/bm800246x10.1021/bm800246x ↗
46. 10.1371/journal.pone.005073310.1371/journal.pone.0050733 ↗
47. 10.1007/s11095-011-0519-110.1007/s11095-011-0519-1 ↗
48. 10.1007/s11095-009-0045-610.1007/s11095-009-0045-6 ↗
49. 10.1002/adfm.20170547510.1002/adfm.201705475 ↗
50. 10.1021/ma202725c10.1021/ma202725c ↗
51. 10.1039/c3ra40227d10.1039/c3ra40227d ↗